Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression

Molecular Psychiatry

Volumn 23, Issue 4, 2018, Pages 824-832

  Esterlis, I ^a,b   DellaGioia, N ^a   Pietrzak, R H ^a,b   Matuskey, D ^a   Nabulsi, N ^a   Abdallah, C G ^a,b   Yang, J ^c   Pittenger, C ^a   Sanacora, G ^a   Krystal, J H ^a,b   Parsey, R V ^c,d   Carson, R E ^a,e   DeLorenzo, C ^c,d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d St Francis Hospital The Heart Center   (United States)

^e Yale University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; CARBON; CARBON-11; GLUTAMIC ACID; GRM5 PROTEIN, HUMAN; KETAMINE; METABOTROPIC RECEPTOR 5;

ADULT; BRAIN; CASE CONTROL STUDY; DEPRESSION; DIAGNOSTIC IMAGING; DRUG EFFECT; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; METABOLISM; POSITRON EMISSION TOMOGRAPHY; PROCEDURES;

ADULT; ANTIDEPRESSIVE AGENTS; BRAIN; CARBON RADIOISOTOPES; CASE-CONTROL STUDIES; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GLUTAMIC ACID; HUMANS; KETAMINE; MALE; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, METABOTROPIC GLUTAMATE 5;

EID: 85017517936     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2017.58     Document Type: Article

References (80)

1. Global Burden of Disease Study Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 386: 743–800. DOI: 10.1016/S0140-6736(15)60692-4
2. World Health Organization The Global Burden of Disease: 2004 Update, Table A2: Burden of Disease in DALYs by Cause, Sex and Income Group in WHO Regions, Estimates for 2004. WHO: Geneva, Switzerland, 2008; http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_AnnexA.pdf.
3. McClintock S, Husain M, Wisniewski S, Nierenberg A, Stewart J, Trivedi M et al. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol 2011; 31: 180–186. DOI: 10.1097/JCP.0b013e31820ebd2c
4. Zisook S, Ganadjian K, Moutier C, Prather R, Rao S. Sequenced Treatment Alternatives to Relieve Depression (STAR*D): lessons learned. J Clin Psychiatry 2008; 69: 1184–1185. DOI: 10.4088/JCP.v69n0719
5. Krystal J, Mathew S, D'Souza D, Garakani A, Gunduz-Bruce H, Charney D. Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs 2010; 24: 669–693. DOI: 10.2165/11533230-000000000-00000
6. Krystal J, Sanacora G, Duman R. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 2013; 73: 1133–1141. DOI: 10.1016/j.biopsych.2013.03.026
7. Sanacora G, Zarate CAJ, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008; 7: 426–437. DOI: 10.1038/nrd2462
8. Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 2007; 62: 1310–1316. DOI: 10.1016/j.biopsych.2007.03.017
9. Abdallah C, Mason G, DellaGioia N, Sanacora G, Jiang L, Matuskey D et al. mGluR5 and glutamate involvement in MDD: a multimodal imaging study. Biol Psychiatry, (under review).
10. Sanacora G, Gueorguieva R, Epperson C, Wu Y-T, Appel M, Rothman D et al. Subtype-specific alterations of GABA and glutamate in major depression. Arch Gen Psychiatry 2004; 61: 705–713. DOI: 10.1001/archpsyc.61.7.705
11. DeLorenzo C, DellaGioia N, Bloch M, Sanacora G, Nabulsi N, Abdallah C et al. In vivo ketamine-induced changes in [11C]ABP688 binding to metabotropic glutamate receptor subtype 5. Biol Psychiatry 2015; 77: 266–275. DOI: 10.1016/j.biopsych.2014.06.024
12. Miyake N, Skinbjerg M, Easwaramoorthy B, Kumar D, Girgis R, Xu X et al. Imaging changes in glutamate transmission in vivo with the metabotropic glutamate receptor 5 tracer [11C] ABP688 and N-acetylcysteine challenge. Biol Psychiatry 2011; 69: 822–824. DOI: 10.1016/j.biopsych.2010.12.023
13. Luykx J, Laban K, Heuvel Mvd, Boks M, Mandl R, Kahn R et al. Region and state specific glutamate downregulation in major depressive disorder: a meta-analysis of (1)H-MRS findings. Neurosci Biobehav Rev 2012; 36: 198–205. DOI: 10.1016/j.neubiorev.2011.05.014
14. Hasler G, Veen Jvd, Tumonis T, Meyers N, Shen J, Drevets W. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 2007; 64: 193–200. DOI: 10.1001/archpsyc.64.2.193
15. Sistiaga A, Herrero I, Conquet F, Sánchez-Prieto J. The metabotropic glutamate receptor 1 is not involved in the facilitation of glutamate release in cerebrocortical nerve terminals. Neuropharmacology 1998; 37: 1485–1492. DOI: 10.1016/S0028-3908(98)00129-4
16. Manahan-Vaughan D, Braunewell K. Novelty acquisition is associated with induction of hippocampal long-term depression. Proc Natl Acad Sci USA 1999; 96: 8739–8744. DOI: 10.1073/pnas.96.15.8739
17. Shigemoto R, Kinoshita A, Wada E, Nomura S, Ohishi H, Takada M et al. Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J Neurosci 1997; 17: 7503–7522. DOI: 10.1523/JNEUROSCI.17-19-07503.1997
18. Takumi Y, Matsubara A, Rinvik E, Ottersen O. The arrangement of glutamate receptors in excitatory synapses. Ann NY Acad Sci 1999; 868: 474–482. DOI: 10.1111/j.1749-6632.1999.tb11316.x
19. Hubert G, Paquet M, Smith Y. Differential subcellular localization of mGluR1a and mGluR5 in the rat and monkey substantia nigra. J Neurosci 2001; 21: 1838–1847. DOI: 10.1523/JNEUROSCI.21-06-01838.2001
20. López-Bendito G, Shigemoto R, Fairén A, Luján R. Differential distribution of group I metabotropic glutamate receptors during rat cortical development. Cereb Cortex 2002; 12: 625–638. DOI: 10.1093/cercor/12.6.625
21. O'Malley K, Jong Y, Gonchar Y, Burkhalter A, Romano C. Activation of metabotropic glutamate receptor mGlu5 on nuclear membranes mediates intranuclear Ca2+ changes in heterologous cell types and neurons. J Biol Chem 2003; 278: 28210–28219. DOI: 10.1074/jbc.M300792200
22. Shin S, Kwon O, Kang JI, Kwon S, Oh S, Choi J et al. mGluR5 in the nucleus accumbens is critical for promoting resilience to chronic stress. Nat Neurosci 2015; 18: 1017–1024. DOI: 10.1038/nn.4028
23. Kovacevic T, Skelin I, Minuzzi L, Rosa-Neto P, Diksic M. Reduced metabotropic glutamate receptor 5 in the Flinders Sensitive Line of rats, an animal model of depression: an autoradiographic study. Brain Res Bull 2012; 87: 406–412. DOI: 10.1016/j.brainresbull.2012.01.010
24. Wieronska JM, Branski P, Szewczyk B, Palucha A, Papp M, Gruca P et al. Changes in the expression of metabotropic glutamate receptor 5 (mGluR5) in the rat hippocampus in an animal model of depression. Pol J Pharmacol 2001; 53: 659–662.
25. Fatemi SH, Folsom TD, Rooney RJ, Thuras PD. mRNA and protein expression for novel GABAA receptors theta and rho2 are altered in schizophrenia and mood disorders; relevance to FMRP-mGluR5 signaling pathway. Transl Psychiatry 2013; 3: e271. DOI: 10.1038/tp.2013.46
26. Deschwanden A, Karolewicz B, Feyissa AM, Treyer V, Ametamey SM, Johayem A et al. Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study. Am J Psychiatry 2011; 168: 727–734. DOI: 10.1176/appi.ajp.2011.09111607
27. Matosin N, Fernandez-Enright F, Frank E, Deng C, Wong J, Huang XF et al. Metabotropic glutamate receptor mGluR2/3 and mGluR5 binding in the anterior cingulate cortex in psychotic and nonpsychotic depression, bipolar disorder and schizophrenia: implications for novel mGluR-based therapeutics. J Psychiatry Neurosci 2014; 39: 407–416. DOI: 10.1503/jpn.130242
28. Smialowska M, Szewczyk B, Branski P, Wieronska JM, Palucha A, Bajkowska M et al. Effect of chronic imipramine or electroconvulsive shock on the expression of mGluR1a and mGluR5a immunoreactivity in rat brain hippocampus. Neuropharmacology 2002; 42: 1016–1023. DOI: 10.1016/S0028-3908(02)00062-X
29. Berman R, Cappiello A, Anand A, Oren D, Heninger G, Charney D et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47: 351–354. DOI: 10.1016/S0006-3223(99)00230-9
30. Abdallah C, Adams T, Kelmendi B, Esterlis I, Sanacora G, Krystal J. Ketamine's mechanism of action: a path to rapid-acting antidepressants. Depress Anxiety 2016; 33: 689–697. DOI: 10.1002/da.22501
31. 3C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism. Biol Psychiatry 2012; 71: 1022–1025. DOI: 10.1016/j.biopsych.2011.11.006
32. Chowdhury G, Zhang J, Thomas M, Banasr M, Ma X, Pittman B et al. Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects. Mol Psychiatry 2016; 22: 120–126. DOI: 10.1038/mp.2016.34
33. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–389. DOI: 10.1192/bjp.134.4.382
34. Beck S, Ward C, Mendelsohn M, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561–571. DOI: 10.1001/archpsyc.1961.01710120031004
35. Bremner J, Krystal J, Putnam F, Southwick S, Marmar C, Charney D et al. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress 1999; 11: 125–136. DOI: 10.1023/A:1024465317902
36. Norcross J, Guadagnoli E, Prochaska J. Factor structure of the profile of mood states (POMs), two partial replications. J Clin Psychol 1984; 40: 1270–1277. DOI: 10.1002/1097-4679(198409)40:5<1270::AID-JCLP2270400526>3.0.CO;2-7
37. Sandiego CM, Nabulsi N, Lin SF, Labaree D, Najafzadeh S, Huang Y et al. Studies of the metabotropic glutamate receptor 5 radioligand [(1)(1)C]ABP688 with N-acetylcysteine challenge in rhesus monkeys. Synapse 2013; 67: 489–501. DOI: 10.1002/syn.21656
38. Kawamura K, Yamasaki T, Kumata K, Furutsuka K, Takei M, Wakizaka H et al. Binding potential of (E)-[(11)C]ABP688 to metabotropic glutamate receptor subtype 5 is decreased by the inclusion of its (11)C-labelled Z-isomer. Nucl Med Biol 2014; 41: 17–23. DOI: 10.1016/j.nucmedbio.2013.09.008
39. Anticevic A, Gancsos M, Murray J, Repovs G, Driesen N, Ennis D et al. NMDA receptor function in large-scale anti-correlated neural systems with implications for cognition and schizophrenia. Proc Natl Acad Sci 2012; 109: 16720–16725. DOI: 10.1073/pnas.1208494109
40. Driesen NR, McCarthy G, Bhagwagar Z, Bloch M, Calhoun V, D'Souza DC et al. Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans. Mol Psychiatry 2013; 18: 1199–1204. DOI: 10.1038/mp.2012.194
41. Ametamey S, Kessler L, Honer M, Wyss M, Buck A, Hintermann S et al. Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. J Nucl Med 2006; 47: 698–705.
42. Rusjan PM, Wilson AA, Bloomfield PM, Vitcu I, Meyer JH, Houle S et al. Quantitation of translocator protein binding in human brain with the novel radioligand [18F]-FEPPA and positron emission tomography. J Cereb Blood Flow Metab 2011; 31: 1807–1816. DOI: 10.1038/jcbfm.2011.55
43. Gallezot JD, Nabulsi N, Neumeister A, Planeta-Wilson B, Williams WA, Singhal T et al. Kinetic modeling of the serotonin 5-HT(1B) receptor radioligand [(11)C]P943 in humans. J Cereb Blood Flow Metab 2010; 30: 196–210. DOI: 10.1038/jcbfm.2009.195
44. Wu S, Ogden RT, Mann JJ, Parsey RV. Optimal metabolite curve fitting for kinetic modeling of 11C-WAY-100635. J Nucl Med 2007; 48: 926–931. DOI: 10.2967/jnumed.106.038075
45. DeLorenzo C, Milak MS, Brennan KG, Kumar JS, Mann JJ, Parsey RV. In vivo positron emission tomography imaging with [(11)C]ABP688: binding variability and specificity for the metabotropic glutamate receptor subtype 5 in baboons. Eur J Nucl Med Mol Imaging 2011; 38: 1083–1094. DOI: 10.1007/s00259-010-1723-7
46. DeLorenzo C, Kumar JS, Mann JJ, Parsey RV. In vivo variation in metabotropic glutamate receptor subtype 5 binding using positron emission tomography and [11C]ABP688. J Cereb Blood Flow Metab 2011; 31: 2169–2180. DOI: 10.1038/jcbfm.2011.105
47. DeLorenzo C, Klein A, Mikhno A, Gray N, Zanderigo F, Mann JJ et al A New Method for Assessing PET-MRI Coregistration. Proceedings of SPIE; 7 February 2009; Lake Buena Vista, Florida, USA.
48. Treyer V, Streffer J, Wyss MT, Bettio A, Ametamey SM, Fischer U et al. Evaluation of the metabotropic glutamate receptor subtype 5 using PET and 11C-ABP688: assessment of methods. J Nucl Med 2007; 48: 1207–1215. DOI: 10.2967/jnumed.107.039578
49. Patel S, Hamill T, Connolly B, Jagoda E, Li W, Gibson R. Species differences in mGluR5 binding sites in mammalian central nervous system determined using in vitro binding with [18F]F-PEB. Nucl Med Biol 2007; 34: 1009–1017. DOI: 10.1016/j.nucmedbio.2007.07.009
50. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 1533–1539. DOI: 10.1038/sj.jcbfm.9600493
51. Hirvonen J, Johansson J, Teras M, Oikonen V, Lumme V, Virsu P et al. Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [11C]PE2I: quantitative modeling and test-retest reproducibility. J Cereb Blood Flow Metab 2008; 28: 1059–1069. DOI: 10.1038/sj.jcbfm.9600607
52. Parker R, Flint E, Bosworth H, Pieper C, Steffens D. A three-factor analytic model of the MADRS in geriatric depression. Int J Geriatr Psychiatry 2003; 18: 73–77. DOI: 10.1002/gps.776
53. Huang C, Chen J. Meta-analysis of the factor structures of the Beck Depression Inventory-II. Assessment 2015; 22: 459–472. DOI: 10.1177/1073191114548873
54. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997; 17: 2921–2927. DOI: 10.1523/JNEUROSCI.17-08-02921.1997
55. Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 2016; 533: 481–486. DOI: 10.1038/nature17998
56. Duman R, Aghajanian G, Sanacora G, Krystal J. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med 2016; 22: 238–249. DOI: 10.1038/nm.4050
57. Kim H, Lee K, Lee D, Han Y, Lee S, Sohn J et al. Costimulation of AMPA and metabotropic glutamate receptors underlies phospholipase C activation by glutamate in hippocampus. J Neurosci 2015; 35: 6401–6412. DOI: 10.1523/JNEUROSCI.4208-14.2015
58. Lorrain D, Baccei C, Bristow L, Anderson J, Varney M. Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 2003; 117: 697–706. DOI: 10.1016/S0306-4522(02)00652-8
59. Bartolomeis Ad, Sarappa C, Buonaguro E, Marmo F, Eramo A, Tomasetti C et al. Different effects of the NMDA receptor antagonists ketamine, MK-801, and memantine on postsynaptic density transcripts and their topography: role of Homer signaling, and implications for novel antipsychotic and pro-cognitive targets in psychosis. Prog Neuropsychopharmacol Biol Psychiatry 2013; 46: 1–12. DOI: 10.1016/j.pnpbp.2013.06.010
60. 11C]ABP688. J Cereb Blood Flow Metab 2011; 31: 2169–2180. DOI: 10.1038/jcbfm.2011.105
61. DeLorenzo C, Gallezot J, Gardus J, Yang J, Planeta B, Nabulsi N et al. In vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [11C]ABP688 and [18F]FPEB JCBFM. J Cereb Blood Flow Metab 2016 (e-pub ahead of print).
62. Attwell D, Buchan AM, Charpak S, Lauritzen M, Macvicar BA, Newman EA. Glial and neuronal control of brain blood flow. Nature 2010; 468: 232–243. DOI: 10.1038/nature09613
63. Kågedal M, Cselényi Z, Nyberg S, Raboisson P, Ståhle L, Stenkrona P et al. A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066 - estimating occupancy in the absence of a reference region. Neuroimage 2013; 82: 160–169. DOI: 10.1016/j.neuroimage.2013.05.006
64. Abdallah C, Sanacora G, Duman R, Krystal J. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu Rev Med 2015; 66: 509–523. DOI: 10.1146/annurev-med-053013-062946
65. Li N, Lee B, Liu R, Banasr M, Dwyer J, Iwata M et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010; 329: 959–964. DOI: 10.1126/science.1190287
66. Pałucha A, Brański P, Szewczyk B, Wierońska J, Kłak K, Pilc A. Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacol Biochem Behav 2005; 81: 901–906. DOI: 10.1016/j.pbb.2005.06.015
67. Tatarczyńska E, Klodzińska A, Chojnacka-Wójcik E, Palucha A, Gasparini F, Kuhn R et al. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol 2001; 132: 1423–1430. DOI: 10.1038/sj.bjp.0703923
68. Pałucha-Poniewiera A, Wierońska J, Brański P, Burnat G, Chruścicka B, Pilc A. Is the mGlu5 receptor a possible target for new antidepressant drugs? Pharmacol Rep 2013; 65: 1506–1511. DOI: 10.1016/S1734-1140(13)71511-1
69. Quiroz JA, Tamburri P, Deptula D, Banken L, Beyer U, Rabbia M et al. Efficacy and safety of basimglurant as adjunctive therapy for major depression: a randomized clinical trial. JAMA Psychiatry 2016; 73: 675–684. DOI: 10.1001/jamapsychiatry.2016.0838
70. Iijima M, Fukumoto K, Chaki S. Acute and sustained effects of a metabotropic glutamate 5 receptor antagonist in the novelty-suppressed feeding test. Behav Brain Res 2012; 235: 287–292. DOI: 10.1016/j.bbr.2012.08.016
71. Fontanez-Nuin D, Santini E, Quirk G, Porter J. Memory for fear extinction requires mGluR5-mediated activation of infralimbic neurons. Cereb Cortex 2011; 21: 727–735. DOI: 10.1093/cercor/bhq147
72. Chen L, Liu J, Ali U, Gui Z, Hou C, Fan L et al. Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist produces anxiolytic-like effects and reverses abnormal firing activity of projection neurons in the basolateral nucleus of the amygdala in rats with bilateral 6-OHDA lesions. Brain Res Bull 2011; 84: 215–223. DOI: 10.1016/j.brainresbull.2011.01.005
73. Molina-Hernández M, Tellez-Alcántara N, Pérez-García J, Olivera-Lopez J, Jaramillo M. Antidepressant-like and anxiolytic-like actions of the mGlu5 receptor antagonist MTEP, microinjected into lateral septal nuclei of male Wistar rats. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1129–1135. DOI: 10.1016/j.pnpbp.2006.04.022
74. Mora MPdl, Lara-García D, Jacobsen K, Vázquez-García M, Crespo-Ramírez M, Flores-Gracia C et al. Anxiolytic-like effects of the selective metabotropic glutamate receptor 5 antagonist MPEP after its intra-amygdaloid microinjection in three different non-conditioned rat models of anxiety. Eur J Neurosci 2006; 23: 2749–2759. DOI: 10.1111/j.1460-9568.2006.04798.x
75. Page G, Khidir F, Pain S, Barrier L, Fauconneau B, Guillard O et al. Group I metabotropic glutamate receptors activate the p70S6 kinase via both mammalian target of rapamycin (mTOR) and extracellular signal-regulated kinase (ERK 1/2) signaling pathways in rat striatal and hippocampal synaptoneurosomes. Neurochem Int 2006; 49: 413–421. DOI: 10.1016/j.neuint.2006.01.020
76. Hou L, Klann E. Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression. J Neurosci 2004; 24: 6352–6361. DOI: 10.1523/JNEUROSCI.0995-04.2004
77. Breier A, Malhotra A, Pinals D, Weisenfeld N, Pickar D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 1997; 154: 805–811. DOI: 10.1176/ajp.154.6.805
78. Vollenweider F, Leenders K, Scharfetter C, Antonini A, Maguire P, Missimer J et al. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose(FDG). Eur Neuropsychopharmacol 1997; 7: 9–24. DOI: 10.1016/S0924-977X(96)00039-9
79. Rowland L, Beason-Held L, Tamminga C, Holcomb H. The interactive effects of ketamine and nicotine on human cerebral blood flow. Psychopharmacology 2010; 208: 575–584. DOI: 10.1007/s00213-009-1758-2
80. Akkus F, Ametamey S, Treyer V, Burger C, Johayem A, Umbricht D et al. Marked global reduction in mGluR5 receptor binding in smokers and ex-smokers determined by [11C]ABP688 positron emission tomography. Proc Natl Acad Sci USA 2013; 110: 334. DOI: 10.1073/pnas.1210984110